Roche’s $3.5B Buy of 89bio Could Shift Fatty Liver Treatment Game
Swiss pharma giant Roche has announced an agreement to acquire U.S. biotech firm 89bio for up to US$3.5 billion. The deal includes US$2.4B upfront plus contingent payments tied to clinical…
